

THE UTILIZATION OF EXERCISE TESTS IN EVALUATING PATIENTS WITH PULMONARY VASCULAR DISEASE

Abdullah AlShimemeri*¹, Itani M², Alghadeer H³, Al-Jahdali H³,
Al-Moamary M³, A. Al-Duhaim A³, Mobeireek⁴, Andrew Nassif⁵

¹Intensive Care Department, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia

²Rafik Hariri University Hospital, Beirut – Lebanon

³Department of Medicine, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

⁴King Saud University, Riyadh, Saudi Arabia

⁵Branston university, Las Vegas, NV, USA

*Corresponding Author Contact Information:
ABDULLAH AL-SHIMEMERI, MD, MBChB, FCCP, EDIC, FRCP(C)
Executive Director, Health Promotion Center
Associate Professor, College of Medicine
King Saud Bin Abdulaziz University for Health Sciences
Consultant, Pulmonary & Critical Care Medicine
King Abdulaziz Medical City, King Fahad National Guard Hospital
P.O. Box 22490 Riyadh 11426, K.S.A.
Email: aftercom@yahoo.com

Abstract

Purpose: It is known that patients with pulmonary hypertension show an augmented ventilatory response to exercise defined as the slope of minute ventilation over carbon dioxide production (VE/VCO₂). We suggested that the degree of ventilatory augmentation may be used to differentiate between patients with primary pulmonary hypertension (PPH), Eisenmenger (E.) and chronic thromboembolic (CH.TH.EM.) disease.

Methods: We retrospectively reviewed the incremental exercise tests of 14 patients with E. disease, 9 patients with PPH and 7 patients with CH.TH.EM disease. These patients had no spirometric evidence of airway obstruction or restriction.

Conclusion: An exaggerated ventilatory response to exercise was found among patients with CH.TH.EM related pulmonary hypertension which is more profound than Eisenmenger and PPH patients. Finding an exaggerated ventilatory response to exercise may suggest CH.TH.EM in patients with PH and normal spirometry. **Vixra JGSP 2013 (3): 111-112.**

Key words: pulmonary vascular diseases, primary pulmonary hypertension, Cardiopulmonary Exercise Testing, chronic thromboembolic diseases, Eisenmenger, Riyadh, Saudi Arabia

Abbreviations used: (PPH) primary pulmonary hypertension, (E.) Eisenmenger, (CH.TH.EM.) chronic thromboembolic disease, (CO₂) carbon dioxide, (COPD) Chronic Obstructive Pulmonary Disease, (CTEPH) chronic thromboembolic pulmonary hypertension, (CPET) Cardiopulmonary Exercise Testing, (VO₂ peak) Maximal oxygen uptake, (PAH) pulmonary arterial hypertension, (IPF) Idiopathic pulmonary fibrosis, (VE-/VCO₂) ventilatory equivalents for carbon dioxide production, (SpO₂) arterial oxygen saturation, (6MWD) 6-min walking distance, (CHF) chronic heart failure, (VE) minute ventilation, (VO₂max) maximal oxygen consumption, (VT) volume, (RR) respiratory rate, (PETCO₂) end-tidal Pco₂, (BTPS) barometric pressure, and water vapor, (SE) standard error, (VE%MVV) maximal ventilation-minute voluntary volume ratio, (PETCO₂max) maximal end-tidal pressure for carbon dioxide, (VD/VT) dead-space to tidal volume ratio, (VE/VCO₂) ventilatory equivalent ratio for carbon dioxide

INTRODUCTION

Exercise intolerance due to limited oxygen in the blood has been linked to higher mortality rates across a range of diseases. An individual's inability to meet the energy requirements of a chosen or imposed task generally results in exercise intolerance. The perception of limb fatigue, breathlessness or even pain is noted when there is any impaired function that is affecting the transfer of oxygen from the atmosphere to the contracting muscles.^[1] This limited oxygen transfer affects muscles which in turn affects exercise. Respiratory muscle weakness contributes to a variety of issues including hypercapnia – a condition where there is too much carbon dioxide (CO₂) in the blood, dyspnoea – shortness of breath, and nocturnal oxygen desaturation. It has

also been observed where patients with severe muscle weakness due to steroid-induced myopathy were met with higher mortality rates. In terms of stronger muscles, inspiratory muscle strength has been shown to correlate significantly with walking distance.^[36] Exercise intolerance has been shown to be one of the most important predictors of mortality in a broad range of diseases, including COPD, PPH, interstitial lung disease, pulmonary hypertension, chronic heart failure and cystic fibrosis.^[36]

The effects of oxygen transfer inability have been shown in a study on cardiopulmonary exercise testing and lung and heart-lung transplantation. Schwaiblmair et al. showed that lung and heart-lung transplant recipients demonstrated severe exercise intolerance prior to transplantation. After transplantation, the same recipients reached maximum oxygen uptakes in the range of 22 to 71% of predicted values. This showed peak oxygen uptake was increased after transplantation.^[34]

Exercise testing has been used to show the difference between normal versus abnormal physiological systems. Exercise testing is commonly based on the principle that physiological systems begin to reach their functional limits under stress. Therefore, stressing the organ systems to a level at which abnormality becomes discernible from the magnitude or profile of response of appropriately selected variables can reflect the capability of those particular systems.^[1] Stressing organ systems gradually through increments provides an improved standardized measure. Incremental exercise tests involving gradual added stress which span the entire tolerance range are a commonly accepted measure. The results provide information on normal versus abnormal responses, sites of functional failure, effective operating range of systems,

and they also provide a reference for training and rehabilitation. ^[1] In terms of abnormal information provided, exercise tests have been used as a diagnostic tool for cardiac disease for some time, but in recent years they have become more frequently used in diagnosis and monitoring of pulmonary disorders. Exercise tests diagnose and help understand disease stage severity and are therefore valuable in guiding pharmacological and nonpharmacological treatment and action plans. ^[1]

In terms of abnormal respiratory information, unexplained dyspnoea during exercise is a frequent reason for exercise testing. Dyspnoea, impaired exercise tolerance and reduced quality of life are common complaints in patients with chronic respiratory disease. ^[36] Saleemi, in a paper on chronic thromboembolic pulmonary hypertension (CTEPH) explains that CTEPH patients with advanced stages of this respiratory disease experience progressive dyspnoea on exertion, along with other complications. Without intervention, mortality rates are approximately 70%. ^[39] Exercise testing is important in both cardiopulmonary and respiratory diseases.

Cardiopulmonary Exercise Testing (CPET) is the standard test used in measuring and assessing exercise tolerance. In healthy children and adults, highly trained athletes, and patients with moderate exercise impairment due to chronic disease, repeated measurements obtained during cardiopulmonary exercise tests have generally shown good reliability and reproducibility. ^[37] CPET has been advised in a number of conditions including evaluation of exercise tolerance, evaluation of patients with cardiovascular diseases and evaluation of patients with respiratory diseases/symptoms. ^[2] It is considered the gold standard to study a patient's level of exercise limitation and its causes. The

American College of Chest Physicians statement is that CPET provides a more global assessment of integrative exercise responses which measurement of individual organ system functions does not provide. It is because of this that CPET is gaining widespread clinical usage for evaluating undiagnosed exercise intolerance. This in turn has led to increasingly acceptance for CPET in patient management. It has been found that health status correlates better with exercise tolerance rather than with resting measurements. CPET should be considered when specific questions remain unanswered after consideration of basic clinical data such as patient history, and physical examination. With CPET a wide variety variables can be measured. ^[30]

A study by Hansen et al. questioned whether severe disability such as heart failure, could increase variability and decrease the confidence interpretation of CPET key measurements. The study found high reproducibility of the key physiologic measurements as was found in other studies involving heart, lung, musculoskeletal, and renal disease with less severe exercise impairment. The study concluded that well-conducted gas exchange exercise tests can safely and reliably measure key and discriminating exercise variables, including VO_2 peak, in moderately to very severely impaired children and adults. VO_2 peak is the highest level of oxygen uptake at peak exercise during test performance. Taken alone, a change in VO_2 peak of 8 to 10% might be used as a cut off in deciding that there is a significant change in exercise tolerance. ^[37]

The patients in this study with pulmonary arterial hypertension (PAH) appear to be more impaired than those in any previously report CPET reproducibility study of patients with either cardiovascular or pulmonary diseases. In using CPETs to

evaluate and follow up PAH patients, these tests were used to assess patient performance variability and evaluate reading variability. This study found that CPET measurements can be safely, reliably, and reproducibly assessed even in patients with severe exercise intolerance.

CPET is increasingly being used for the clinical evaluation of patients with respiratory diseases.^[12] Idiopathic pulmonary fibrosis (IPF), a progressive form of lung disease, is characterized by progressive dyspnoea and impaired gas exchange which lead to mortality. In a study on the prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis, Flaherty hypothesized that maximal oxygen uptake during cardiopulmonary exercise testing would predict mortality in IPF patients. The mean survival from time of diagnosis to death is three years. The study found that in IPF, gas exchange worsens with exercise. The study concluded that maximal oxygen uptake below 8.3 ml/kg/min during CPET increased risk of death for patients with IPF.^[40] Lung transplantation, for IPF patients under 55 years of age and without complicating medical illness, is a viable option.^[38]

CPET results show the pattern of deviation of abnormal response from the normal response and therefore indicate impairments of physiological systems based on pattern of abnormality.^[1]

Exercise indices have been shown to be better indicators of health than resting measures. Exercise indices such as VO_2 peak; ventilatory equivalents for carbon dioxide production (V_E/V_{CO_2}) which indicate how many liters of air breathed to eliminate 1 liter of CO_2 ; and arterial oxygen saturation (S_pO_2) which indicates an estimation of arterial hemoglobin oxygen saturation, have in fact proven to be better predictors of

prognosis than lung function measurements obtained at rest.^[3] In sports medicine, criterion used to define a subject's exercise capacity has classically been based on VO_2 peak standardized by weight where in normal values for healthy young adults is in the range of 35-45 mL·min⁻¹·kg⁻¹.^[33]

Exercise tolerance is known to be a predictor of mortality in patients with pulmonary and cardiovascular disease. In PPH specifically, exercise indices that have been shown to predict prognosis of patients include VO_2 peak, arterial desaturation, and 6-min walking distance (6MWD). VO_2 peak has been reported as a significant predictor of survival in PPH. VO_2 peak less than or equal to 10.4 mL·min⁻¹·kg is associated with a 50% risk of death at 1 yr and this significantly increases in the second year; however, the risk decreases to 10% at 1 yr and 30% in the second year if VO_2 peak is greater than 10.4 mL·min⁻¹·kg. Adding peak systolic blood pressure into the equation increased the predictive value of VO_2 peak where patients with a VO_2 peak less than or equal to 10.4 mL·min⁻¹·kg and a peak systolic blood pressure of less than 120 mmHg have a worse prognosis than those with only one of the two risk factors. Patients with PPH showed that the 6MWD correlates well with VO_2 peak W

here patients who walked greater than 332 meter had a 90% survival rate as compared to those who walked less than 332 meters who had a survival rate of 20%. Overall, higher levels of oxygen in the blood equated to higher chances of survival; therefore, the evaluation of exercise tolerance through CPET and the 6MWT in patients with lung and heart disease is of great prognostic value.^[32]

We suggest that the degree of ventilatory augmentation may be used to differentiate between patients with primary pulmonary

hypertension (PPH), Eisenmenger (E.) and chronic thromboembolic (CH.TH.EM) disease. Abnormalities in cardiopulmonary responses to incremental cycle ergometer exercise are often similar in obstructive, restrictive and pulmonary vascular disorders. All are characterized by an accelerated ventilatory response, primarily as a result of the effects of high fixed physiological dead space, combined, in many cases with attendant arterial oxygen desaturation. The breathing pattern is more rapid and shallow in both obstructive and restrictive lung disorders compare to health. In general, respiratory frequency responses to exercise are most pronounced in patients with restrictive lung disease.

Exercise testing along with respiratory measurements may gain more insight into disease. Symptoms scores for dyspnoea and exertion have been shown to be valuable tools during exercise testing, at both peak exercise and specific time points during testing.^[36] Exercise is often limited by intolerable symptoms of dyspnoea, leg discomfort or a combination of both of these well before the physiological boundaries of the respiratory and cardiovascular systems are reached.^[12] Dyspnoea is connected with physical activity therefore it is necessary to understand methods for assessing symptoms associated with exercise.^[1]

LITERATURE REVIEW

Pulmonary hypertension has been defined as a mean Ppa of >25 mmHg at rest or >30 mmHg during exercise.^[4] Pulmonary hypertension is noted to be consistently associated with reduced exercise capacity wherein it has recently been shown that peak $\dot{V}O_2$ correlates significantly with New York Heart Association symptom class in patients with primary pulmonary

hypertension.^[5, 6] Patients with pulmonary hypertension are noted to have both resting hyperventilation and also excessive ventilation for any given exercise load.^[7, 8] CPET can uncover abnormalities in the integrated functions of the cardiovascular, respiratory, metabolic, peripheral muscle and neurosensory systems. The ventilatory response to exercise is usually abnormal across the spectrum of more advanced pulmonary disorders. Ventilatory index is used in assessment of Ventilatory limitation.^[12]

In patients with chronic heart failure (CHF), several observations relate heart failure severity to hyperventilation. Hyperventilation is associated with dyspnoea, one of the most common symptoms of CHF. An abnormally increased minute ventilation (VE) – volume of air exhaled from the lungs in 1 minute – requirement is one of the limiting factors of exercise capacity. And a low ventilatory efficiency which is high VE when compared to \dot{V}_{CO_2} is a strong negative prognostic predictor, independent of $\dot{V}O_{2\text{ peak}}$. Hyperventilation during exercise in CHF may be due to alteration in lung mechanics, reduced lung diffusion, and increased ventilatory requirements. In CHF patients compared with healthy individuals, CPET typically reveals reductions in $\dot{V}O_{2\text{ peak}}$. CPET is a very important tool in assessing the prognosis of cardiac patients and choosing effective treatment. CPET is useful in evaluating the degree of exercise limitation and identifying underlying causes.^[35]

Patients with obstructive lung disease exhibit several ventilatory abnormalities such as an increased dead space ventilation, a reduced ventilatory reserve, an increased work of breathing, and mechanical problems related to the position of the diaphragm.^[9, 10] The factors that contribute to dyspnoea in

patients with pulmonary disorders such as COPD are related to a combination of high ventilator requirement coupled with low ventilatory capacity.^[11]

Pulmonary hypertension should be suspected when ventilatory responses to exercise are abnormally elevated in the presence of relatively preserved spirometric parameters.^[12]

The maximal oxygen consumption ($VO_2\text{max}$) is considered to provide an index of severity wherein it is noted to be lower in patients with high pulmonary vascular resistance and lower cardiac index. Further, it is also significantly correlated with the amount of functional vascular bed.^[13-15] Reductions in VO_2 peak reflected reduced cardiac output according to the study conducted on patients with primary pulmonary hypertension.^[4] Studies have indicated that non-hypoxic pulmonary hypertension patients have a greater exercise capacity and a larger SLOPE (VE/VCO_2) which reflects worsened ventilation – perfusion inequality.^[16]

The slope of VE/VCO_2 is consistently elevated when compared to health, as is the ventilator equivalent at the ventilatory threshold. Studies have also indicated that the VE/VCO_2 ratio correlates well with hemodynamic indices of pulmonary hypertension.^[3, 4]

The measurements of the ventilatory response to exercise were suggested as a noninvasive screening test for pulmonary hypertension.^[6] The 6-min walk test (6MWT) and CPET are currently proposed for diagnostic, therapeutic and prognostic finalities of pulmonary vascular disorders. Field testing and incremental exercise testing have complementary value in assessment for pulmonary rehabilitation. The 6MWT is easy to perform and is attractive as it is more relevant to daily living.^[36] As a field test,

due to its simplicity and inexpensive nature, the 6MWT is gaining widespread usage in identifying an individual's functional capacity and exercise limitation, and is determining intervention. Since walking is a common form of activity for most people, walk tests are favorable for usage among elderly and frail populations, of whom make up the majority of patients with chronic respiratory and cardiac disease. As walk test standardization improves, field test information derived from walk test is expected to be optimized.^[31]

Considered an incremental test, CPET is thought to be highly reproducible and provides remarkable insights into the pathophysiological mechanisms that lead to exercise intolerance.^[17] This incremental exercise test is the standard test used when studying cardiovascular, pulmonary and metabolic adaptations to exercise in cardiac patients. The majority of cardiopulmonary exercise tests in cardiac diseases are performed in patients with chronic heart failure. $VO_2\text{ peak}$ is the most well known and widely used variable obtained from CPET. $V'O_2\text{ peak}$ less than $10\text{ mL}\cdot\text{min}\cdot\text{kg}^{-1}$ is associated with poor prognosis, while $V'O_2\text{ peak}$ greater than $16\text{ mL}\cdot\text{min}\cdot\text{kg}^{-1}$ is associated with good prognosis.^[35]

MATERIAL AND METHODS

Subjects

We retrospectively reviewed the incremental exercise tests of 14 patients with E. disease, 9 patients with PPH and 7 patients with CH.TH.EM disease.

Study Protocol

The study protocol involved the performance of baseline pulmonary function tests as well as maximal symptom-limited incremental

exercise on cycle ergometer. Ergometry assesses exercise capacity in order to determine level of exercise intolerance, identify contributing factors of exercise limitation, and investigate risk of exercise.^[36]

Spirometry was performed with the subject in a seated position with a calibrated electronic spirometer (System 1070 Medical Graphics Corporation, St. Paul, Minn). Lung volumes were determined by body box plethysmography (PK Morgan Limited, England). Maximum voluntary ventilation was measured as previously described.^[18]

Exercise was performed on an electrically braked cycle ergometer (Mijnhardt) with stepwise increasing workloads of 15 W every 2 min. Subjects were seated, wore a nose clip, and breathed through a mouthpiece into a modified low-resistance two-way valve (model 6115, Hans Rudolph Inc, Kansas City, Mo). Expiratory gases were analyzed breath by breath with a computerized exercise system (System 2001, Medical Graphics Corporation, St. Paul, Minn). The breath-by-breath signal was integrated by the system computer to yield 15-s moving averages of minute ventilation (VE), tidal volume (VT), respiratory rate (RR), VO_2 , VCO_2 , and end-tidal P_{CO_2} ($PETCO_2$). Air flow and gas measurements were corrected for ambient temperature, barometric pressure, and water vapor, and expressed in BTPS units. Exercise equipment was calibrated prior to each study with gases of known concentrations and a 3-L calibration syringe.

Determinations of levels of dyspnoea were obtained by having the subjects rate their "degree of shortness of breath" according to the modified Borg scale (0 = none to 10 = maximal dyspnoea).^[19]

Mean values of pulmonary are reported as mean \pm standard error (SE) of the mean. Ninety-five percent confidence limits for normal control subjects were established as previously described.^[20] Regression lines for exercise relationships were determined by least squares method.^[20]

RESULTS

The data from the three subject groups has been summarized in tables 1 and 2. The study included 14 patients with E. disease, 9 patients with PPH and 7 patients with CH.TH.EM. disease. The patients suffering from Eisenmenger disease and PPH were in their middle age, while the patients with CH.TH.EM. were in their early 50s. The predicted percentages of F_{evl} , F_{VC} , and TLC were almost equivalent across the three groups. These patients had no spirometric evidence of airway obstruction or restriction. VE/VCO_2 max was significantly higher in the CH.TH.EM (78.8 ± 10.3) compared to Eisenmenger (60.3 ± 4.1) and PPH (56.8 ± 6.9) groups. The exercise parameters revealed some significant results. The $VO_{2max\%}$ in subjects with CH.TH.EM (73.0 ± 32.6) was significantly higher than the E (43.7 ± 6.2) and PPH (41.0 ± 10.3) subjects.

Table 1

Parameter	Eisenmenger	PPH	CH.TH.EM.
Age, yr	35.6 ± 2.9	38.1 ± 3.2	50.0 ± 6.1
Fev ₁ , % predicted	82.1 ± 4.6	80.6 ± 4.2	84.3 ± 9.5
FVC, % predicted	80.7 ± 4.7	79.2 ± 4.8	84.0 ± 7.9
TLC%pred	100 ± 2.9	93.5 ± 4.6	89.3 ± 13.2

Table 1- Baseline Characteristics

There were no significant difference in most of the other values such as the Max VE%MVV, VTmax, Max Resp. rate and PETCO₂max. Some amount of difference was noted in the VD/VTmax between the CH.TH.EM, E and PPH groups but the values were not significant.

However, VO₂/h rate max and VE/VCO₂ max were significantly higher in CH.TH.EM. (11.9 + 6.2 & 78.8 ± 10.3) compared to Eisenmenger (5.9 ± 0.7 & 60.3 ± 4.1) and PPH (5.6 ± 1.0 & 56.8 ± 6.9) groups.

Table 2

Parameter	Eisenmenger	PPH	CH.TH.EM.
VO ₂ max%pred	43.7 ± 6.2	41.0 ± 10.3	73.0 ± 32.6
Max V _E %MVV	53.1 ± 6.1	49.8 ± 5.6	50.0 ± 6.41
V _T max, liter	1.30 ± 0.1	1.25 ± 0.1	1.20 ± 0.05
Max Resp. rate	35.9 ± 2.0	34.0 ± 3.5	39.6 ± 3.9
PETCO ₂ max	21.2 ± 1.26	24.4 ± 2.9	18.9 ± 3.3
V _D /V _T max%	22.5 ± 1.5	23.6 ± 2.5	30.1 ± 2.
V _{O₂} /h. rate max	5.9 ± 0.7	5.6 ± 1.0	11.9 ± 6.2

$V_E/V_{CO_2 \text{ max}}$	60.3 ± 4.1	56.8 ± 6.9	78.8 ± 10.3
----------------------------	----------------	----------------	-----------------

Table 2: lists the exercise parameters (Values are means \pm SE.)

DISCUSSION

Pulmonary thromboembolic disease has been noted to have a wide variety of clinical presentations. The spectrum of thromboembolic diseases can range from acute minor pulmonary embolism to chronic thromboembolic pulmonary hypertension.^[21]

The $VO_2\text{max}\%$ in subjects with CH.TH.EM (73.0 ± 32.6) disease was noted to be significantly higher than the E (43.7 ± 6.2) and PPH (41.0 ± 10.3) subjects. This was evident although other parameters such as the Max $VE\%MVV$, VT_{max} , Max Resp. rate and $PETCO_2\text{max}$ were not different amongst all the three groups. Excessive ventilation is generally attributed either to an increase in the dead space ventilation (inadequate perfusion of ventilated lung areas) or to alveolar hyperventilation due to a decreased $PaCO_2$ set point.^[6]

Pulmonary embolism has been noted to result in an abnormal alveolar dead space that is expired in synchrony with gas from normally perfused alveoli. This feature of pulmonary embolism separates the condition from other pulmonary diseases affecting the airways, which are characterized by nonsynchronous emptying of compartments with an uneven ventilation/perfusion relationship.^[22, 23]

The $VD/V_{t\text{max}}$ scores were also comparatively higher in CH.TH.EM. disease than others. It has been demonstrated that the increase in physiologic dead space to tidal volume (VD/VT) had comparable sensitivity and specificity to radioisotope scanning in

the diagnosis of pulmonary emboli. The high VD/VT leads to high dead space ventilation.²² The VE/V_{CO_2} ratio will be higher than the normal when the VD/VT ratio is high or the patient hyperventilates.^[24]

Maximal O_2 utilization has been noted to be directly proportional to the maximal level of cardiac output. On the other hand, it is inversely proportional to the pulmonary vascular resistance and the level of pulmonary arterial pressure.^[13] Janicki et al concluded that determination of $VO_2 \text{ max}$ had a potential of becoming the practical screening method for the identification and prediction of the severity of pulmonary vascular diseases.^[13]

The ventilatory and/or circulatory disturbances present in patients with chronic lung disorders impair the response to exercise.^[25] The response to a standard exercise regimen across different individuals can vary according to the load in relation to the maximum load an individual can tolerate. Thereby, maximum workload expressed as $VO_2 \text{ max}$ can be studied to differentiate the chronic lung disorders. A high oxygen pulse at $VO_2 \text{ max}$, according to studies can rule out severe pulmonary artery hypertension.^[25]

It is widely known that exercise results in abnormally large increases in the pulmonary artery pressure in individuals suffering from pulmonary vascular disease.^[26] Studies have noted that VO_2 kinetics may be limited by pulmonary hemodynamics in the presence of disease.^[27]

Further, it was also noted that the VO_2/h rate max was significantly higher in CH.TH.EM. (11.9 ± 6.2) compared to Eisenmenger (5.9 ± 0.7) and PPH (5.6 ± 1.0) groups. A

significant difference was also noted in the VE/VCO₂ scores. Thereby, an exaggerated response becomes evident with the finding that although there was not much difference in the Max VE%MVV, VT_{max}, Max Resp. rate and PETCO₂max scores, the VO₂ and VE/VCO₂ were significantly higher in subjects with CH.TH.EM disease.

The partial pressure of end-tidal carbon dioxide (PETCO₂max) was comparatively lower in subjects with CH.TH.EM disease. Studies have demonstrated that abnormally high positive arterial to end-tidal PCO₂ difference at rest almost completely separates patients with pulmonary embolism from those without. However, a high degree of overlap with patients with obstructive or restrictive lung disease may be noted.^[28] Nevertheless, if the positive arterial to end-tidal PCO₂ remains positive during exercise, this is evidence for decreased perfusion to ventilated alveoli.^[29] Further, it should be noted that PETCO₂ is lower than PaCO₂ in diseases with ventilation-perfusion mismatching.^[24]

Our study demonstrated that the ventilatory responses were altered in patients with pulmonary hypertension, Eisenmenger disease and chronic thromboembolic disease. Further, it was also noted that VE/VCO₂ max was significantly higher in the CH.TH.EM. (78.8 ± 10.3) compared to Eisenmenger (60.3 ± 4.1) and PPH (56.8 ± 6.9) groups. Janicki and colleagues demonstrated using cardiopulmonary exercise testing that the peak exercise oxygen consumption (peak VO₂) was decreased and the regression slope relating minute ventilation to carbon dioxide output (VE-VCO₂ slope) was increased in patients with chronic thromboembolic disease.^[5] Thereby the findings from our studies suggest that exaggerated ventilatory response to exercise may suggest CH.TH.EM in patients with pulmonary

hypertension and normal spirometry.

Conclusion

An exaggerated ventilatory response to exercise was found among patients with CH.TH.EM related pulmonary hypertension which is more profound than Eisenmenger and PPH patients. Finding an exaggerated ventilatory response to exercise may suggest CH.TH.EM in patients with pulmonary hypertension and normal spirometry.

REFERENCES

1. Whipp BJ, Wagner PD, Agusti A. Determinants of the physiological systems responses to muscular exercise in healthy subjects. *Eur Respir Mon.* 2007; 40:1–35
2. Weisman IM, Zeballos RJ. Cardiopulmonary exercise testing. *Pulm Crit Care Update* 1995; 11:1–9.
3. Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary Exercise Testing in the Functional and Prognostic Evaluation of Patients with Pulmonary Diseases. *Respiration* 2009; 77:3-17.
4. Hatano S, Strasser T, eds. Primary Pulmonary Hypertension: Report on a World Health Organization Meeting. Geneva, World Health Organization, 1975.
5. Markowitz DH, Systrom DM. Diagnosis of pulmonary vascular limit to exercise by cardiopulmonary exercise testing. *J Heart Lung Transplant* 2004; 23: 88–95.
6. Sun XG, Hansen JR, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. *Circulation* 2001; 104:

- 429–435.
7. Theodore J, Jamieson SW, Burke CM, Reitz BA, Stinson EB, Van Kessel A, et al. Physiologic aspects of human heart-lung transplantation: pulmonary function status of the post-transplanted lung. *Chest* 1984; 86:349-57
 8. Theodore J, Robin ED, Morris AJ, Burke CM, Jamieson SW, Van Kessel A, Stinson EB, Shumway NE. Augmented ventilatory response to exercise in pulmonary hypertension. *Chest*. 1986 Jan; 89(1):39-44.
 9. Loke J, Mahler DA, Man SFP, Wiedemann HP, Mathay RA. Exercise impairment in chronic obstructive pulmonary disease. *Clin Chest Med* 1984; 5:121-43
 10. Brown HV, Wasserman K. Exercise performance in chronic obstructive pulmonary diseases. *Med Clin North Am* 1981; 65:525-47
 11. Vogiatzis I, Williamson AF, Miles J, Taylor IK. Physiological Response to Moderate Exercise Workloads in a Pulmonary Rehabilitation Program in Patients With Varying Degrees of Airflow Obstruction. *Chest* 1999; 116: 1200-1207.
 12. O'Donnell DE, Laveneziana P. Patterns of cardiopulmonary response to exercise in lung diseases. *Eur Respir Mon*, 2007, 40, 69–92.
 13. Janicki JS, Weber KT, Likoff MJ, Fishman AP. Exercise testing to evaluate patients with pulmonary vascular disease. *Am Rev Respir Dis* 1984; 129:S93–S95.
 14. D'Alonzo GE, Gianotti L, Dantzker DR. Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. *Am Rev Respir Dis* 1986; 133:1984–1990.
 15. Systrom DM, Cockrill BA, Hales CA. Exercise testing in patients with vascular disease. In: Weisman IM, Zeballos RJ, editors. *Clinical exercise testing*. Basel, Switzerland: Karger; 2002. p. 200–204.
 16. Mitani R, Haraguchi M, Takata S, et al. Excessive Ventilatory Response During Exercise in Patients With Non-Hypoxic Pulmonary Hypertension. *Circ J* 2002; 66: 453 –456.
 17. Guazzi M, Opasich C. Functional evaluation of patients with chronic pulmonary hypertension. *Ital Heart J*. 2005 Oct; 6(10):789-94.
 18. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy non-smoking adults. *Am Rev Respir Dis* 1971; 103:57-67.
 19. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Exerc* 1982; 14:377-81.
 20. Colton T. *Statistics in medicine*. Boston: Little, Brown & Co, 1974.
 21. de Perrot M, Fadel E, McRae K, Tan K, Slinger P, Paul N, Mak S, Granton JT. Evaluation of persistent pulmonary hypertension after acute pulmonary embolism. *Chest*. 2007 Sep; 132(3):780-5. Epub 2007 Mar 30.
 22. Burki NK: The dead space to tidal volume ratio in the diagnosis of pulmonary embolism. *Am Rev Respir Dis* 1986; 133:679-685.
 23. Bhagat R, Schreiber G. Abnormalities on Cardiopulmonary Exercise Test in a

- Dyspneic Patient. *Respiration* 2002;69:543-546
24. Wasserman K, Hansen JE, Sue DY. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 4 Ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
 25. Schrijen F, Ferrara G, Romero Colomer P, Sadoul P. Is it possible to predict pulmonary arterial hypertension from an exercise test? *G Ital Cardiol.* 1984; 14 Suppl 1:56-60.
 26. Raeside DA, Smith A, Brown A, Patel KR, Madhok R, Cleland J, Peacock AJ. Pulmonary artery pressure measurement during exercise testing in patients with suspected pulmonary hypertension. *Eur Respir J.* 2000 Aug; 16(2):282-7.
 27. Sietsema KE. Oxygen uptake kinetics in response to exercise in patients with pulmonary vascular disease. *Am Rev Respir Dis.* 1992 May; 145(5):1052-7.
 28. Eriksson L, Wollmer P, Olsson CG, Albrechtsson U, Larusdottir H, Nilsson R, Sjogren A, Jonson B. Diagnosis of pulmonary embolism based upon alveolar dead space analysis. *Chest* 1989; 96:357-362.
 29. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ. Principles of Exercise Testing and Interpretation, ed 3. Philadelphia: Lippincott Williams & Wilkins; 1999.A
 30. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med* Vol 167. Pp211-277, 2003.
 31. Singh S. Walking for the assessment of patients with chronic obstructive pulmonary disease. *Eur Respir Mon,* 2007, 40, 148-164.
 32. Palange P, Antonucci G. Exercise testing in the prognostic evaluation of patients with lung and heart diseases. *Eur Respir Mon,* 2007, 40, 195-207.
 33. Puente-Maestu L. Reference values in adults. *Eur Respir Mon,* 2007, 40, 165-185.
 34. Schwaiblmair M, Reichenspurner H, Muller C, Briegel H, Groh J, Reichart B, Vogelmeier C. Cardiopulmonary exercise testing before and after lung and heart-lung transplantation. *Am J Respir Crit Care med* Vol 159. Pp 1277-1283, 1999.
 35. Agostoni P, Cattadori G. Patterns of response diagnostic for cardiac disease. *Eur Respir Mon,* 2007, 40, 93-107.
 36. Gosselink R, Troosters T, Langer D, Decramer M. Laboratory tests. *Eur Respir Mon,* 2007, 40, 129-147.
 37. Hansen J, Sun X, Yasunobu Y, Garafano R, Gates G, Barst R, Wasserman K. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension.
 38. Gross T, Hunninghake G. Idiopathic pulmonary fibrosis. *N Engl J Med,* Vol. 345, No. 7. 2001.
 39. Saleemi S. Chronic thromboembolic pulmonary hypertension. *PVRI Review.* Vol. 1. Issue 2. 2009.
 40. Flaherty K. The prognostic value of cardiopulmonary exercise testing in pulmonary fibrosis. *Am J Respir Crit Care Med.* 2009 Mar 1;179(5):402-7